Abeona Therapeutics Inc Institutional ownership
What is the Institutional ownership of Abeona Therapeutics Inc?
The Institutional ownership of Abeona Therapeutics Inc is 10.77%
What is the definition of Institutional ownership?
Institutional Ownership is the amount of a company’s available stock owned by mutual or pension funds, insurance companies, investment firms, endowments or other large entities that manage funds on the behalf of others.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Institutional ownership of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with institutional ownership similar to Abeona Therapeutics Inc
- Molecular Data Inc has Institutional ownership of 10.76%
- Gladstone Commercial Corp has Institutional ownership of 10.76%
- Huanxi Media has Institutional ownership of 10.76%
- TCI Express has Institutional ownership of 10.76%
- Engenco has Institutional ownership of 10.76%
- Aroa Biosurgery has Institutional ownership of 10.76%
- Abeona Therapeutics Inc has Institutional ownership of 10.77%
- Echelon has Institutional ownership of 10.77%
- Opera Ltd has Institutional ownership of 10.78%
- ABB India has Institutional ownership of 10.78%
- Gati has Institutional ownership of 10.78%
- Standard Lithium has Institutional ownership of 10.79%
- BlackRock MuniYield Investment Fund has Institutional ownership of 10.79%